Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,165,165 shares of the company's stock after selling 1,410,337 shares during the quarter. Primecap Management Co. CA owned 10.35% of Elanco Animal Health worth $619,610,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ELAN. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at approximately $35,000. Jones Financial Companies Lllp increased its position in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after acquiring an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. raised its stake in shares of Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after acquiring an additional 3,411 shares during the period. Blue Trust Inc. lifted its holdings in shares of Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares during the last quarter. Finally, Spire Wealth Management boosted its stake in shares of Elanco Animal Health by 107.4% during the 4th quarter. Spire Wealth Management now owns 7,776 shares of the company's stock worth $94,000 after purchasing an additional 4,026 shares during the period. Institutional investors own 97.48% of the company's stock.

Remove Ads

Elanco Animal Health Stock Down 0.3 %

Shares of ELAN stock traded down $0.03 on Friday, hitting $10.55. The stock had a trading volume of 4,166,426 shares, compared to its average volume of 4,661,099. Elanco Animal Health Incorporated has a one year low of $10.03 and a one year high of $18.80. The business has a 50 day moving average price of $11.38 and a 200 day moving average price of $12.64. The company has a market cap of $5.22 billion, a PE ratio of 26.38, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm posted $0.08 EPS. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. Research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business's stock in a transaction dated Friday, March 7th. The shares were purchased at an average price of $10.90 per share, with a total value of $109,000.00. Following the transaction, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. This represents a 10.93 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.57% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ELAN shares. Leerink Partners assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price objective on the stock. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Stifel Nicolaus cut their price objective on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. UBS Group decreased their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Finally, Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of "Hold" and an average price target of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.